Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04698252 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Local Therapy for ER/PR-positive Oligometastatic Breast Cancer

Study acronym: LARA
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 8, 2022 (before its estimated April 1, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv4
  2. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Mar 1, 2024 to Apr 1, 2024
    • Study completion date: Mar 1, 2031 to Apr 1, 2031
    • Start date changed from estimate of Mar 1, 2021 to Apr 1, 2021
  3. Start date: Jan 1, 2021 to Mar 1, 2021
    • Primary completion date: Jan 1, 2024 to Mar 1, 2024
    • Study completion date: Jan 1, 2031 to Mar 1, 2031
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Randomized phase 2 trial to evaluate the efficacy of local therapy for oligometastasis from ER/PR-positive breast cancer. The study hypothesis is that local therapy in addition to systemic therapy improves progression-free survival in comparison with systemic therapy alone.
Trial Details
NCT Number NCT04698252
Lead Sponsor Instituto do Cancer do Estado de São Paulo
Conditions
(from sponsor)		 Breast Cancer
Related terms Breast Neoplasms
Enrollment 74 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov